A subcutaneous version of Daiichi Sankyo’s AstraZeneca-partnered blockbuster antibody-drug conjugate (ADC) Enhertu could be ...

Winners received prestigious award in recognition of latest innovations in advancement in life sciences ...

ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca.

At an event held in the House of Lords on 5th November, The Trade Facilitation Commission released their detailed report and ...

Carebook Technologies Inc. ("Carebook" or the "Company") (XETR: PMM1), a leading Canadian provider of innovative digital health solutions, will release its financial results for the quarter ended ...

Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous ...

AstraZeneca Plc started the week with a market valuation of about £171 billion ($222 billion). By the close on Thursday it ...

AstraZeneca has revealed that its top executive in China, Leon Wang, has been detained by Chinese authorities, after ...

The "Cancer Antibody Drug Conjugates Market Size, Drugs Approval, Price, Sales & Clinical Trials Insight 2030" report has been added to ResearchAndMarkets.com's offering. Antibody drug conjugates ...

datopotamab deruxtecan is one of the three lead ADCs in the oncology pipeline of Daiichi Sankyo, and one of the most advanced ...

Three phase 3 trials of combinations including datopotamab deruxtecan for the treatment of non–small cell lung cancer are beginning.